Stock News

$-0.43 EPS Expected for Intellia Therapeutics Inc. (NTLA); Enersys (ENS)’s Sentiment Is 0.93

Analysts expect Intellia Therapeutics Inc. (NASDAQ:NTLA) to report $-0.43 EPS on March, 13.They anticipate $0.12 EPS change or 38.71% from last quarter’s $-0.31 EPS. After having $-0.44 EPS previously, Intellia Therapeutics Inc.’s analysts see -2.27% EPS growth. The stock increased 2.23% or $0.555 during the last trading session, reaching $25.495. About 55,155 shares traded. Intellia Therapeutics Inc. (NASDAQ:NTLA) has declined 46.16% since February 21, 2017 and is downtrending. It has underperformed by 62.86% the S&P500.

EnerSys manufactures, markets, and distributes industrial batteries. The company has market cap of $3.00 billion. The firm offers chargers, outdoor cabinet enclosures, power equipment, and battery accessories, as well as related after-market and customer-support services for industrial batteries. It has a 31.46 P/E ratio. It also provides reserve power products that are used for backup power for the continuous operation of critical applications in telecommunications systems, uninterruptible power systems applications for computer and computer-controlled systems, and other specialty power applications, including medical and security systems, premium starting, lighting, and ignition applications, as well as in switchgear, electrical control systems used in electric utilities, large-scale energy storage, energy pipelines, commercial aircraft, satellites, military aircraft, submarines, ships, and tactical vehicles.

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company has market cap of $1.08 billion. The firm develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. It currently has negative earnings. The Company’s ex vivo pipeline includes proprietary and partnered programs focuses on chimeric antigen receptor T cells and hematopoietic stem cells.

Among 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellia Therapeutics had 5 analyst reports since May 31, 2016 according to SRatingsIntel. The stock of Intellia Therapeutics Inc. (NASDAQ:NTLA) earned “Outperform” rating by Leerink Swann on Friday, August 5. The stock of Intellia Therapeutics Inc. (NASDAQ:NTLA) earned “Outperform” rating by Wedbush on Tuesday, May 31. The stock has “Hold” rating by Jefferies on Tuesday, May 31. The stock of Intellia Therapeutics Inc. (NASDAQ:NTLA) earned “Buy” rating by Jefferies on Friday, August 5. Credit Suisse initiated the stock with “Outperform” rating in Tuesday, May 31 report.

The stock decreased 0.98% or $0.705 during the last trading session, reaching $71.575. About 34,522 shares traded. EnerSys (ENS) has risen 40.27% since February 21, 2017 and is uptrending. It has outperformed by 23.57% the S&P500.

Analysts await EnerSys (NYSE:ENS) to report earnings on May, 3. They expect $1.23 earnings per share, down 3.91% or $0.05 from last year’s $1.28 per share. ENS’s profit will be $51.55M for 14.55 P/E if the $1.23 EPS becomes a reality. After $1.25 actual earnings per share reported by EnerSys for the previous quarter, Wall Street now forecasts -1.60% negative EPS growth.

Leave a Reply

Your email address will not be published. Required fields are marked *